Evidence map›Paper›PMID 40464310›Full record

ArticleThe Australasian journal of dermatology2025

Lymphomatoid Papulosis Following Spesolimab Treatment for Generalised Pustular Psoriasis.

Mizuho Namba, Mika Matsumoto, Naoya Saito, Atsuko Kimura, Chihiro Sagara, Daiki Rokunohe, Eijiro Akasaka

Abstract readCase Reports
In one paragraph

Article in The Australasian journal of dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mizuho NambaDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0009-0004-1929-4114
Mika MatsumotoDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0002-8197-1858
Naoya SaitoDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0009-0004-4001-202X
Atsuko KimuraDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0009-0006-1827-9099
Chihiro SagaraDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0001-6925-1068
Daiki RokunoheDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0002-2509-4483
Eijiro AkasakaDepartment of Dermatology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.ORCID https://orcid.org/0000-0003-0866-8032

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

CD30 ligandlymphomalymphomatoid papulosispsoriasisspesolimab

Identifiers

PMID40464310
PMCPMC12334809

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.